贝康医疗-B(02170)预计上半年收入约1.27亿元至1.38亿元同比增长约49%至62%

智通财经网07-12

智通财经APP讯，贝康医疗-B(02170)发布公告，2024年1月1日至6月30日期间，集团收入约人民币1.27亿元至1.38亿元，同比增长约49%至62%。收入增加主要由于以下原因所致：(i)集团收购新加坡BMX Holdco Pte. Ltd. 后将其财务业绩合并纳入集团的全球销售业绩。集团已构建了广泛的全球销售网络，在海外业绩持续保持增长的同时集团实现了国内自主开发产品的国际销售。于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2450312177?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_36.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2024-07-12 06:47","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2450312177","market":"sg","top_or_hot":-1,"title":"贝康医疗-B(02170)预计上半年收入约1.27亿元至1.38亿元 同比增长约49%至62%","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，贝康医疗-B(02170)发布公告，2024年1月1日至6月30日期间，集团收入约人民币1.27亿元至1.38亿元，同比增长约49%至62%。收入增加主要由于以下原因所致：(i)集团收购新加坡BMX Holdco Pte. Ltd.  后将其财务业绩合并纳入集团的全球销售业绩。集团已构建了广泛的全球销售网络，在海外业绩持续保持增长的同时集团实现了国内自主开发产品的国际销售。于...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1149740.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>贝康医疗-B(02170)预计上半年收入约1.27亿元至1.38亿元 同比增长约49%至62%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n贝康医疗-B(02170)预计上半年收入约1.27亿元至1.38亿元 同比增长约49%至62%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-12 06:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1149740.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，贝康医疗-B(02170)发布公告，2024年1月1日至6月30日期间，集团收入约人民币1.27亿元至1.38亿元，同比增长约49%至62%。收入增加主要由于以下原因所致：(i)集团收购新加坡BMX Holdco Pte. Ltd.  后将其财务业绩合并纳入集团的全球销售业绩。集团已构建了广泛的全球销售网络，在海外业绩持续保持增长的同时集团实现了国内自主开发产品的国际销售。于...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1149740.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1149740.html","article_id":"2450312177","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_36.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2450312177","pubTimestamp":1720738034,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"贝康医疗-B(02170)发布公告，2024年1月1日至6月30日期间，集团收入约...","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1597":"三胎概念","02170":"贝康医疗-B","BK1222":"医疗保健用品"},"translate_title":"Beikang Medical-B (02170) expects revenue in the first half of the year to be approximately 127 million to 138 million yuan, a year-on-year increase of approximately 49% to 62%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02170":1},"content_text":"智通财经APP讯，贝康医疗-B(02170)发布公告，2024年1月1日至6月30日期间，集团收入约人民币1.27亿元至1.38亿元，同比增长约49%至62%。收入增加主要由于以下原因所致：(i)集团收购新加坡BMX Holdco Pte. Ltd.  后将其财务业绩合并纳入集团的全球销售业绩。集团已构建了广泛的全球销售网络，在海外业绩持续保持增长的同时集团实现了国内自主开发产品的国际销售。于上半年，集团向西班牙、英国、美国等地客户销售的胚胎培养箱等设备及胚胎培养液等产品的销量实现了显着增长并成功开发了多个集团客户。集团预期将在下半年实现向多个新客户的产品交付;及(ii)中国业务保持稳健增长。在中国多省市将辅助生殖部分项目纳入医保范畴的激励政策下，公司五大场景下的核心产品的销售保持了稳健增长。PGT试剂盒、胚胎培养箱及超低温存储产品的销量均实现预期增速。集团在销售试剂、设备和耗材的同时，还向客户提供软件和其他配套的支持。集团预期在辅助生殖领域激励政策的不断推出下，集团在中国的销售规模将会持续增长。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2450312177"}

贝康医疗-B(02170)预计上半年收入约1.27亿元至1.38亿元 同比增长约49%至62%

精彩评论

贝康医疗-B(02170)预计上半年收入约1.27亿元至1.38亿元同比增长约49%至62%